EIP
JSPRW icon

Easterly Investment Partners’s Japer Therapeutics Warrants JSPRW Stock Holding History

Easterly Investment Partners’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$15K – 210
2021
Q3 		$15K Hold
10,000
– – ﹤0.01% 257
2021
Q2 		$12K Hold
10,000
– – ﹤0.01% 184
2021
Q1 		$8K Hold
10,000
– – ﹤0.01% 181
2020
Q4 		$15K Hold
10,000
– – ﹤0.01% 129
2020
Q3 		$12K Hold
10,000
– – ﹤0.01% 103
2020
Q2 		$10K Buy
+10,000
New +$6.22K ﹤0.01% 92

Other funds holding JSPRW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Easterly Investment Partners's JSPRW Position: Q4 2021 in Review

Easterly Investment Partners sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2021, closing a stake of 10,000 shares — an estimated $15K sold.

Easterly Investment Partners first reported a position in JSPRW in Q2 2020 and held it in 6 quarters. The position peaked at $15K in Q3 2021. 15 funds tracked by Wall St. Rank hold JSPRW as of Q4 2021.

  • Easterly Investment Partners reported no remaining Japer Therapeutics Warrants position as of Q4 2021 after selling out during the quarter.
  • Easterly Investment Partners sold 10,000 Japer Therapeutics Warrants shares in Q4 2021, an estimated $15K.
  • Easterly Investment Partners first reported a position in Japer Therapeutics Warrants in Q2 2020 and held it in 6 quarters.
  • Easterly Investment Partners's Japer Therapeutics Warrants position peaked at $15K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2021.

Based on Easterly Investment Partners's 13F filing for Q4 2021, filed 8 Feb 2022.